The Svelte IDS and RX platforms utilize low-compliant balloon material and proprietary Balloon Control Bands (BCBs) which control balloon growth during stent expansion and allow multiple, safe post-dilatations to minimize procedure time and cost. Both platforms also employ a new class of bioresorbable drug carrier composed of naturally-occurring amino acids (PEAs) which provides high mechanical integrity and elicits reduced inflammatory response compared with competitive (PLGA) technologies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/16/13 | $22,000,000 |
Clark Enterprises New Science Ventures | undisclosed | |
| 03/10/14 | $5,000,000 |
West Health Investment Fund | undisclosed |
